Matching articles for "ustekinumab"
Issue 1730 · June 9, 2025
Guselkumab (Tremfya) — An IL-23 Antagonist for Crohn's Disease

The injectable interleukin (IL)-23 antagonist guselkumab ( Tremfya – Janssen Biotech) has now been approved by the FDA for treatment of moderately to severely active Crohn's disease (CD) in adults; it was…

Med Lett Drugs Ther. 2025 Jun 9; 67(1730):92-4 doi:10.58347/tml.2025.1730c
The injectable interleukin (IL)-23 antagonist guselkumab ( Tremfya – Janssen Biotech) has now been approved by the FDA for treatment of moderately to severely active Crohn's disease (CD) in adults; it was approved earlier for treatment of ulcerative colitis (UC), plaque psoriasis, and psoriatic arthritis. The IL-23 antagonists risankizumab (Skyrizi) and mirikizumab (Omvoh) and the IL-12/23 antagonist ustekinumab ( Stelara , and biosimilars) are also approved for treatment of CD.
Issue 1728 · May 12, 2025
Mirikizumab (Omvoh) — An IL-23 Antagonist for Crohn's Disease

The injectable interleukin (IL)-23 antagonist mirikizumab-mrkz ( Omvoh – Lilly) is now FDA-approved for treatment of moderately to severely active Crohn's disease (CD) in adults. Mirikizumab was approved in…

Med Lett Drugs Ther. 2025 May 12; 67(1728):78-80 doi:10.58347/tml.2025.1728d
The injectable interleukin (IL)-23 antagonist mirikizumab-mrkz ( Omvoh – Lilly) is now FDA-approved for treatment of moderately to severely active Crohn's disease (CD) in adults. Mirikizumab was approved in 2023 for treatment of ulcerative colitis. Two other IL-23 antagonists, risankizumab (Skyrizi) and guselkumab (Tremfya) , are also approved for treatment of CD.
Issue 1724 · March 17, 2025
Guselkumab (Tremfya) for Ulcerative Colitis

The interleukin (IL)-23 antagonist guselkumab ( Tremfya – Janssen Biotech) has now been approved by the FDA for treatment of moderately to severely active ulcerative colitis (UC) in adults; it was approved…

Med Lett Drugs Ther. 2025 Mar 17; 67(1724):46-8 doi:10.58347/tml.2025.1724d
The interleukin (IL)-23 antagonist guselkumab ( Tremfya – Janssen Biotech) has now been approved by the FDA for treatment of moderately to severely active ulcerative colitis (UC) in adults; it was approved earlier for treatment of plaque psoriasis and psoriatic arthritis. Guselkumab is the third IL-23 antagonist to be approved in the US for treatment of UC; risankizumab (Skyrizi) and mirikizumab (Omvoh) were approved earlier.
Issue 1715 · November 11, 2024
Risankizumab (Skyrizi) for Ulcerative Colitis

The injectable interleukin (IL)-23 antagonist risankizumab-rzza ( Skyrizi – Abbvie), previously approved by the FDA for treatment of Crohn's disease (CD), has now been approved for treatment of moderately to…

Med Lett Drugs Ther. 2024 Nov 11; 66(1715):182-4 doi:10.58347/tml.2024.1715d
The injectable interleukin (IL)-23 antagonist risankizumab-rzza ( Skyrizi – Abbvie), previously approved by the FDA for treatment of Crohn's disease (CD), has now been approved for treatment of moderately to severely active ulcerative colitis (UC) in adults. Risankizumab is the first IL-23 antagonist to be approved for treatment of both CD and UC. It is also approved for treatment of plaque psoriasis and psoriatic arthritis.
Issue 1712 · September 30, 2024
Drugs for Plaque Psoriasis

Mild to moderate plaque psoriasis can be treated with topical drugs and phototherapy. Patients with moderate to severe disease generally require systemic therapy. Guidelines for the treatment of psoriasis with…

Med Lett Drugs Ther. 2024 Sep 30; 66(1712):153-60 doi:10.58347/tml.2024.1712a
Mild to moderate plaque psoriasis can be treated with topical drugs and phototherapy. Patients with moderate to severe disease generally require systemic therapy. Guidelines for the treatment of psoriasis with topical therapy, phototherapy, and systemic drugs have recently been published.
Issue 1712 · September 30, 2024
Comparison Table: Some Drugs for Plaque Psoriasis (online only)

View the Comparison Table: Some Drugs for Plaque Psoriasis

Med Lett Drugs Ther. 2024 Sep 30; 66(1712):e160-6 doi:10.58347/tml.2024.1712b
View the Comparison Table: Some Drugs for Plaque Psoriasis
Issue 1707 · July 22, 2024 Free
In Brief: Wezlana — An Ustekinumab Biosimilar Interchangeable with Stelara

The FDA has approved ustekinumab-auub ( Wezlana – Amgen), an interchangeable biosimilar product similar to the interleukin-12 and -23 antagonist Stelara , for treatment of the same indications as Stelara…

Med Lett Drugs Ther. 2024 Jul 22; 66(1707):119 doi:10.58347/tml.2024.1707e
The FDA has approved ustekinumab-auub ( Wezlana – Amgen), an interchangeable biosimilar product similar to the interleukin-12 and -23 antagonist Stelara , for treatment of the same indications as Stelara (see Table 1). Wezlana is the first Stelara biosimilar to be approved in the US.
Issue 1698 · March 18, 2024
Mirikizumab (Omvoh) for Ulcerative Colitis

The FDA has approved the interleukin (IL)-23 antagonist mirikizumab-mrkz ( Omvoh – Lilly) for treatment of moderately to severely active ulcerative colitis (UC) in adults. Mirikizumab is the first selective…

Med Lett Drugs Ther. 2024 Mar 18; 66(1698):46-7 doi:10.58347/tml.2024.1698c
The FDA has approved the interleukin (IL)-23 antagonist mirikizumab-mrkz ( Omvoh – Lilly) for treatment of moderately to severely active ulcerative colitis (UC) in adults. Mirikizumab is the first selective IL-23 antagonist to be approved for this indication. Ustekinumab (Stelara) , an IL-12/23 antagonist, was approved for treatment of UC in 2019. The IL-23 antagonist risankizumab (Skyrizi) is approved for treatment of Crohn's disease.
Issue 1694 · January 22, 2024
Bimekizumab (Bimzelx) for Psoriasis

The FDA has approved the injectable interleukin (IL)-17A/17F antagonist bimekizumab-bkzx ( Bimzelx – UCB) for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic…

Med Lett Drugs Ther. 2024 Jan 22; 66(1694):11-3 doi:10.58347/tml.2024.1694b
The FDA has approved the injectable interleukin (IL)-17A/17F antagonist bimekizumab-bkzx ( Bimzelx – UCB) for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic treatment or phototherapy. Bimekizumab is the first IL-17A/17F antagonist to be approved in the US. It was approved in the European Union for the same indication in 2021.
Issue 1690 · November 27, 2023
Etrasimod (Velsipity) for Ulcerative Colitis

The oral sphingosine 1-phosphate (S1P) receptor modulator etrasimod ( Velsipity – Pfizer) has been approved by the FDA for treatment of moderately to severely active ulcerative colitis in adults. It is the…

Med Lett Drugs Ther. 2023 Nov 27; 65(1690):187-9 doi:10.58347/tml.2023.1690b
The oral sphingosine 1-phosphate (S1P) receptor modulator etrasimod ( Velsipity – Pfizer) has been approved by the FDA for treatment of moderately to severely active ulcerative colitis in adults. It is the second oral S1P receptor modulator to be approved in the US for this indication; ozanimod (Zeposia) was the first.
Issue 1680 · July 10, 2023
Drugs for Inflammatory Bowel Disease

Ulcerative colitis (UC) and Crohn's disease (CD), referred to collectively as inflammatory bowel disease (IBD), are chronic immune-mediated inflammatory conditions. Guidelines for treatment of UC and CD have…

Med Lett Drugs Ther. 2023 Jul 10; 65(1680):105-12 doi:10.58347/tml.2023.1680a
Ulcerative colitis (UC) and Crohn's disease (CD), referred to collectively as inflammatory bowel disease (IBD), are chronic immune-mediated inflammatory conditions. Guidelines for treatment of UC and CD have been updated in recent years
Issue 1680 · July 10, 2023
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)

View the Table: Some Drugs for Inflammatory Bowel Disease

Med Lett Drugs Ther. 2023 Jul 10; 65(1680):e115-9 doi:10.58347/tml.2023.1680d
View the Table: Some Drugs for Inflammatory Bowel Disease
Issue 1680 · July 10, 2023
Table: Safety of Drugs for IBD in Pregnancy (online only)

View the Table: Safety of Drugs for IBD in Pregnancy

Med Lett Drugs Ther. 2023 Jul 10; 65(1680):e113 doi:10.58347/tml.2023.1680b
View the Table: Safety of Drugs for IBD in Pregnancy
Issue 1680 · July 10, 2023
Table: Some Drug Interactions with Drugs for IBD (online only)

View the Table: Some Drug Interactions with Drugs for IBD

Med Lett Drugs Ther. 2023 Jul 10; 65(1680):e114 doi:10.58347/tml.2023.1680c
View the Table: Some Drug Interactions with Drugs for IBD
Issue 1666 · December 26, 2022
Risankizumab (Skyrizi) - An IL-23 Antagonist for Crohn's Disease

The injectable interleukin (IL)-23 antagonist risankizumab-rzaa ( Skyrizi – Abbvie) has been approved by the FDA for treatment of moderately to severely active Crohn's disease (CD) in adults. Risankizumab…

Med Lett Drugs Ther. 2022 Dec 26; 64(1666):205-7
The injectable interleukin (IL)-23 antagonist risankizumab-rzaa ( Skyrizi – Abbvie) has been approved by the FDA for treatment of moderately to severely active Crohn's disease (CD) in adults. Risankizumab was approved earlier for treatment of plaque psoriasis and psoriatic arthritis.
Issue 1658 · September 5, 2022
Upadacitinib (Rinvoq): A Second JAK Inhibitor for Ulcerative Colitis

The FDA has approved the oral Janus kinase (JAK) inhibitor upadacitinib ( Rinvoq – Abbvie) for treatment of moderately to severely active ulcerative colitis in adults who have had an inadequate response to…

Med Lett Drugs Ther. 2022 Sep 5; 64(1658):142-4
The FDA has approved the oral Janus kinase (JAK) inhibitor upadacitinib ( Rinvoq – Abbvie) for treatment of moderately to severely active ulcerative colitis in adults who have had an inadequate response to or cannot tolerate one or more tumor necrosis factor (TNF) inhibitors. Upadacitinib is the second JAK inhibitor to be approved for this indication; tofacitinib (Xeljanz) was the first. Upadacitinib is also approved for treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and ankylosing spondylitis.
Issue 1633 · September 20, 2021
Ozanimod (Zeposia) for Ulcerative Colitis

The oral sphingosine 1-phosphate (S1P) receptor modulator ozanimod ( Zeposia – Bristol Myers Squibb) has been approved by the FDA for treatment of adults with moderately to severely active ulcerative…

Med Lett Drugs Ther. 2021 Sep 20; 63(1633):147-51
The oral sphingosine 1-phosphate (S1P) receptor modulator ozanimod ( Zeposia – Bristol Myers Squibb) has been approved by the FDA for treatment of adults with moderately to severely active ulcerative colitis. It is the first S1P receptor modulator to be approved for treatment of ulcerative colitis. Ozanimod was approved in March 2020 for use in adults with relapsing forms of multiple sclerosis.
Issue 1600 · June 15, 2020
Drugs for Atopic Dermatitis

Atopic dermatitis (AD; also known as eczema) is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and…

Med Lett Drugs Ther. 2020 Jun 15; 62(1600):89-96
Atopic dermatitis (AD; also known as eczema) is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and has a relapsing course, often improving by adolescence, but sometimes persisting into (or first appearing in) adulthood or even old age.
Issue 1588 · December 30, 2019
Drugs for Psoriatic Arthritis

Psoriatic arthritis is a chronic inflammatory arthropathy associated with psoriasis. A recent review found that about 20% of patients with psoriasis have psoriatic arthritis. Updated guidelines for treatment…

Med Lett Drugs Ther. 2019 Dec 30; 61(1588):203-10
Psoriatic arthritis is a chronic inflammatory arthropathy associated with psoriasis. A recent review found that about 20% of patients with psoriasis have psoriatic arthritis. Updated guidelines for treatment of psoriatic arthritis have recently been published.
Issue 1574 · June 17, 2019
Drugs for Psoriasis

Mild to moderate psoriasis can be treated with topical drugs or with phototherapy. Patients with moderate to severe disease generally require systemic therapy.

Med Lett Drugs Ther. 2019 Jun 17; 61(1574):89-96
Mild to moderate psoriasis can be treated with topical drugs or with phototherapy. Patients with moderate to severe disease generally require systemic therapy.
Issue 1574 · June 17, 2019
Expanded Table: Some Drugs for Psoriasis (online only)

View the Expanded Table: Some Drugs for Psoriasis

Med Lett Drugs Ther. 2019 Jun 17; 61(1574):e96-103
View the Expanded Table: Some Drugs for Psoriasis
Issue 1573 · June 3, 2019
Risankizumab (Skyrizi) for Psoriasis

The FDA has approved the interleukin (IL)-23 antagonist risankizumab-rzaa ( Skyrizi – Abbvie) for treatment of moderate to severe plaque psoriasis in adults. Risankizumab is the third IL-23 antagonist to be…

Med Lett Drugs Ther. 2019 Jun 3; 61(1573):81-3
The FDA has approved the interleukin (IL)-23 antagonist risankizumab-rzaa ( Skyrizi – Abbvie) for treatment of moderate to severe plaque psoriasis in adults. Risankizumab is the third IL-23 antagonist to be approved for this indication; guselkumab (Tremfya) and tildrakizumab (Ilumya) were approved earlier.
Issue 1563 · January 14, 2019
Tildrakizumab (Ilumya) - Another IL-23 Antagonist for Psoriasis

Tildrakizumab-asmn ( Ilumya – Sun), an interleukin (IL)-23 antagonist, has been approved by the FDA for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or…

Med Lett Drugs Ther. 2019 Jan 14; 61(1563):4-6
Tildrakizumab-asmn ( Ilumya – Sun), an interleukin (IL)-23 antagonist, has been approved by the FDA for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tildrakizumab is the second selective IL-23 antagonist to be approved for this indication; guselkumab (Tremfya) was the first.
Issue 1550 · July 2, 2018
Drugs for Inflammatory Bowel Disease

Management of both ulcerative colitis (UC) and Crohn's disease (CD) is based on disease severity. Disease location (proctitis, left-sided colitis, or extensive colitis) also plays a role in drug selection.…

Med Lett Drugs Ther. 2018 Jul 2; 60(1550):107-14
Management of both ulcerative colitis (UC) and Crohn's disease (CD) is based on disease severity. Disease location (proctitis, left-sided colitis, or extensive colitis) also plays a role in drug selection. Some drugs for induction and maintenance of remission of inflammatory bowel disease (IBD) are listed in Table 1.
Issue 1550 · July 2, 2018
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)

View Expanded Table: Some Drugs for Inflammatory Bowel Disease

Med Lett Drugs Ther. 2018 Jul 2; 60(1550):e117-22
View Expanded Table: Some Drugs for Inflammatory Bowel Disease
Issue 1550 · July 2, 2018
Table: Drugs for Crohn's Disease (online only)

View Table: Drugs for Crohn's Disease

Med Lett Drugs Ther. 2018 Jul 2; 60(1550):e115
View Table: Drugs for Crohn's Disease
Issue 1550 · July 2, 2018
Table: Safety of Drugs for IBD in Pregnancy (online only)

View Table: Safety of Drugs for IBD in Pregnancy

Med Lett Drugs Ther. 2018 Jul 2; 60(1550):e116
View Table: Safety of Drugs for IBD in Pregnancy
Issue 1533 · November 6, 2017
Guselkumab (Tremfya) for Psoriasis

The FDA has approved the interleukin (IL)-23 blocker guselkumab ( Tremfya – Janssen) for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.…

Med Lett Drugs Ther. 2017 Nov 6; 59(1533):179-80
The FDA has approved the interleukin (IL)-23 blocker guselkumab ( Tremfya – Janssen) for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Guselkumab is the first selective IL-23 blocker to become available in the US.
Issue 1525 · July 17, 2017
Brodalumab (Siliq) - Another IL-17A Antagonist for Psoriasis

The FDA has approved brodalumab ( Siliq – Valeant), an injectable human interleukin (IL)-17A receptor antagonist, for treatment of adults with moderate to severe plaque psoriasis who have failed to respond…

Med Lett Drugs Ther. 2017 Jul 17; 59(1525):118-9
The FDA has approved brodalumab ( Siliq – Valeant), an injectable human interleukin (IL)-17A receptor antagonist, for treatment of adults with moderate to severe plaque psoriasis who have failed to respond to other systemic therapies. Brodalumab is the third IL-17A antagonist to be approved in the US for this indication; secukinumab (Cosentyx) and ixekizumab (Taltz) were approved earlier.
Issue 1511 · January 2, 2017
Ustekinumab (Stelara) for Crohn's Disease

The FDA has approved the human interleukin (IL)-12 and -23 antagonist ustekinumab ( Stelara – Janssen Biotech) for treatment of moderately to severely active Crohn's disease in adults who were intolerant of…

Med Lett Drugs Ther. 2017 Jan 2; 59(1511):5-6
The FDA has approved the human interleukin (IL)-12 and -23 antagonist ustekinumab ( Stelara – Janssen Biotech) for treatment of moderately to severely active Crohn's disease in adults who were intolerant of or whose disease was unresponsive to treatment with immunomodulators or corticosteroids, or a tumor necrosis factor (TNF) inhibitor. Ustekinumab was approved earlier for treatment of psoriasis and psoriatic arthritis.
Issue 1494 · May 9, 2016
Ixekizumab (Taltz) - A Second IL-17A Inhibitor for Psoriasis

The FDA has approved ixekizumab ( Taltz – Lilly), an injectable humanized interleukin (IL)-17A antagonist, for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic…

Med Lett Drugs Ther. 2016 May 9; 58(1494):59-60
The FDA has approved ixekizumab ( Taltz – Lilly), an injectable humanized interleukin (IL)-17A antagonist, for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Ixekizumab is the second IL-17A antagonist to be approved for this indication in the US; secukinumab ( Cosentyx – Novartis) was the first.
Issue 1470 · June 8, 2015
Drugs for Psoriasis

Mild to moderate psoriasis is generally treated with topical corticosteroids. Vitamin D analogs and tazarotene are topical alternatives that can be used in combination with topical corticosteroids.…

Med Lett Drugs Ther. 2015 Jun 8; 57(1470):81-4
Mild to moderate psoriasis is generally treated with topical corticosteroids. Vitamin D analogs and tazarotene are topical alternatives that can be used in combination with topical corticosteroids. Phototherapy and systemic therapy, including biologic agents, are recommended for patients with moderate to severe disease.
Issue 1470 · June 8, 2015
Drugs for Psoriatic Arthritis (online only)

Psoriatic arthritis is a chronic inflammatory arthropathy that develops in up to 40% of patients with psoriasis. Several guidelines for treatment of psoriatic arthritis have been published.

Med Lett Drugs Ther. 2015 Jun 8; 57(1470):e88-92
Psoriatic arthritis is a chronic inflammatory arthropathy that develops in up to 40% of patients with psoriasis. Several guidelines for treatment of psoriatic arthritis have been published.
Issue 1465 · March 30, 2015
Secukinumab (Cosentyx) for Psoriasis

Secukinumab ( Cosentyx – Novartis), an injectable human interleukin (IL)-17A antagonist, has been approved by the FDA for treatment of moderate to severe plaque psoriasis in adult patients who are candidates…

Med Lett Drugs Ther. 2015 Mar 30; 57(1465):45-7
Secukinumab ( Cosentyx – Novartis), an injectable human interleukin (IL)-17A antagonist, has been approved by the FDA for treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. It is the first IL-17 inhibitor to be approved for any indication in the US.
Issue 1443 · May 26, 2014
Apremilast (Otezla) for Psoriatic Arthritis

Apremilast ( Otezla – Celgene), an oral phosphodiesterase type-4 (PDE4) inhibitor, has been approved by the FDA for treatment of active psoriatic arthritis in adults. It is the fi rst PDE4 inhibitor to be…

Med Lett Drugs Ther. 2014 May 26; 56(1443):41-2
Apremilast ( Otezla – Celgene), an oral phosphodiesterase type-4 (PDE4) inhibitor, has been approved by the FDA for treatment of active psoriatic arthritis in adults. It is the fi rst PDE4 inhibitor to be approved for this indication.
Issue 1435 · February 3, 2014
Certolizumab Pegol (Cimzia) and Ustekinumab (Stelara) for Psoriatic Arthritis

Certolizumab pegol ( Cimzia – UCB), a tumor necrosis factor (TNF) inhibitor previously approved for treatment of Crohn's disease and rheumatoid arthritis, and ustekinumab ( Stelara – Janssen), a human…

Med Lett Drugs Ther. 2014 Feb 3; 56(1435):10-2
Certolizumab pegol ( Cimzia – UCB), a tumor necrosis factor (TNF) inhibitor previously approved for treatment of Crohn's disease and rheumatoid arthritis, and ustekinumab ( Stelara – Janssen), a human interleukin-12 and -23 antagonist previously approved for treatment of moderate-to-severe plaque psoriasis, have now been approved by the FDA for treatment of active psoriatic arthritis.
Issue 125 · January 1, 2013
Drugs for Acne, Rosacea and Psoriasis

The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens, and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium…

Treat Guidel Med Lett. 2013 Jan; 11(125):1-8
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens, and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium acnes promote development of acne lesions by secreting chemotactic factors that attract leukocytes to the follicle, causing inflammation.
Issue 1333 · March 8, 2010 Free
Addendum: Cost of Ustekinumab (Stelara)

In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7) , footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg syringe.

Med Lett Drugs Ther. 2010 Mar 8; 52(1333):20
In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7) , footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg syringe.
Issue 75 · November 1, 2008
Drugs for Acne, Rosacea and Psoriasis

The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium…

Treat Guidel Med Lett. 2008 Nov; 6(75):75-82
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium acnes promote development of acne lesions by secreting chemotactic factors that attract leukocytes to the follicle, causing inflammation.